An international research team has identified a rare hereditary form of aggressive prostate cancer driven by inherited mutations in the CDK12 gene, challenging the long-standing belief that harmful changes in this gene arise only spontaneously inside tumors.
The findings, published in Cancer Discovery, could enable earlier genetic screening for families at risk.
Researchers from the University of British Columbia, BC Cancer, the Vancouver Coastal Health Research Institute, the University of Washington and institutions in Australia, the Netherlands, Spain and Belgium analyzed genetic data from more than 4,500 patients with aggressive prostate cancer, according to Latercera. They identified five unrelated men who carried inherited CDK12 mutations. All five developed metastatic disease between the ages of 44 and 62.
“Lo sorprendente es que todos los pacientes en los que detectamos esta mutación hereditaria ya presentaban una enfermedad metastásica en el momento del diagnóstico,” said Dr. Alexander Wyatt, senior author and associate professor of urologic sciences at the University of British Columbia, who also holds the UBC Presidential Excellence Chair in Precision Oncology, according to Dailybeirut.
He added that identifying these families earlier offers the chance for more intensive screening while curative treatment options still exist.

Before this study, the scientific community assumed damaging CDK12 mutations occurred only as somatic, or spontaneous, events in tumor cells and could not be inherited. To prove the inherited variants were driving the cancer, the team looked for a distinctive genomic signature left when CDK12 stops functioning.
“Los tumores nos proporcionaron una firma genética que apuntaba directamente a CDK12. Esto nos ofreció pruebas contundentes de que dichas mutaciones heredadas desempeñaban un papel directo en el origen de su cáncer,” said Dr. Sofie Tolmeijer, lead author and postdoctoral researcher in the Wyatt laboratory.
Although inherited CDK12 mutations were found in only about one in 1,000 men with aggressive prostate cancer, the researchers estimate the variant could affect hundreds of families worldwide. Because clinical-grade genetic testing panels already screen for CDK12, adding it to standard hereditary prostate cancer testing is “relativamente sencillo,” Wyatt said, meaning the discovery could move from the laboratory to clinical care much faster than findings that require new diagnostic technology.
The work also raises questions about a possible link to ovarian cancer. Several of the affected men had family histories of the disease, and the team identified a separate individual with ovarian cancer who carried an inherited CDK12 mutation and whose tumor showed the same characteristic genomic changes. Further research is needed to determine whether the mutation increases ovarian cancer risk.
Founded in 1908, the University of British Columbia is a public research university with an annual research budget of $893 million that funds 9,992 projects each year. The institution operates two main campuses near Vancouver and Kelowna and is home to TRIUMF, Canada’s national particle and nuclear physics laboratory, which houses the world’s largest cyclotron.
UBC also established the first Max Planck Institute in North America through a partnership with the Max Planck Society. Among its alumni are four prime ministers, including Justin Trudeau.
“Con los programas adecuados de pruebas genéticas y cribado, imaginamos un futuro donde nadie que herede una de estas mutaciones muera a causa del cáncer,” Wyatt concluded.
Worth a look